Amount of Proteinuria and Duration of Expectant Management in Severe Preeclampsia

Abstract

Objective The aim of the study is to evaluate the association between the amount of proteinuria at the time of diagnosis of preeclampsia with severe features (severe preeclampsia [SPE]) and duration of expectant management (EM) and other perinatal outcomes.

Study Design This is a retrospective cohort study of patients with SPE delivering live, non-anomalous singletons at 23^0/7 to 34^2/7 weeks' estimated gestational age (EGA) at a single tertiary center 2016 to 2018. Patients with proteinuria assessment (24-hour total urine protein or urine protein-to-creatinine ratio extrapolation) within 3 days of SPE diagnosis were included. Patients delivered for an indication other than SPE were excluded. Patients were categorized by amount of proteinuria (mg): none (≤300), mild (301–1,000), moderate (1,001–3,000), and massive (≥3,001). The primary outcome was the proportion of potential EM time achieved (%EM), i.e., days of EM divided by days from SPE diagnosis to 34 weeks. Secondary outcomes included delivery EGA, days of EM, and perinatal outcomes. Bivariable and multivariable analyses compared outcomes across groups.

Results Of 295 patients included, 21% had no proteinuria, 33% mild, 19% moderate, and 27% massive. Groups differed by EGA at diagnosis, age, parity, chronic hypertension, and renal disease. %EM was not significantly different between groups (adjusted β coefficient 4.1 [95% CI −5.3, 13.5] for mild proteinuria vs. none, −4.1 [95% CI −14.9, 6.6] for moderate proteinuria vs. none, and −5.6 [95% CI −16.0, 4.7] for massive proteinuria vs. none). Increasing proteinuria was associated with earlier delivery EGA but only days of EM in the mild versus no proteinuria groups. There was no significant association between proteinuria and maternal composite morbidity, but patients with mild and massive proteinuria had higher odds of neonatal composite morbidities compared with no proteinuria.

Conclusion Among patients with SPE, proteinuria level was not consistently associated with duration of EM. However, patients with the greatest amounts of proteinuria may have worse neonatal and selected maternal outcomes.

Key Points

• Amount of proteinuria was not associated with the duration of expectant management.

• Greater proteinuria was associated with earlier delivery in severe preeclampsia.

• Massive proteinuria in preeclampsia was associated with select adverse maternal and neonatal outcomes.

Keywords

cesarean delivery - hypoxic ischemic encephalopathy - maternal death - intensive care unit - massive proteinuria - placental abruption - pulmonary edema

Note

This was presented as a poster (ID #252) at the 41^st annual Society of Maternal Fetal Medicine conference.

Publikationsverlauf

Eingereicht: 31. Mai 2021

Angenommen: 17. Februar 2022

Artikel online veröffentlicht:
29. Mai 2022

• References

• 1 Gestational Hypertension and Preeclampsia. Gestational hypertension and preeclampsia: ACOG Practice Bulletin Summary, Number 222. Obstet Gynecol 2020; 135 (06) 1492-1495
• 2 Creanga AA, Syverson C, Seed K, Callaghan WM. Pregnancy-related mortality in the United States, 2011-2013. Obstet Gynecol 2017; 130 (02) 366-373
• 3 Cunningham FG, Lindheimer MD. Hypertension in pregnancy. N Engl J Med 1992; 326 (14) 927-932
• 4 Zhang J, Meikle S, Trumble A. Severe maternal morbidity associated with hypertensive disorders in pregnancy in the United States. Hypertens Pregnancy 2003; 22 (02) 203-212
• 5 Buchbinder A, Sibai BM, Caritis S. et al; National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. Am J Obstet Gynecol 2002; 186 (01) 66-71
• 6 Maged AM, Elsherief A, Hassan H. et al. Maternal, fetal, and neonatal outcomes among different types of hypertensive disorders associating pregnancy needing intensive care management. J Matern Fetal Neonatal Med 2020; 33 (02) 314-321
• 7 Sibai BM, Mercer BM, Schiff E, Friedman SA. Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: a randomized controlled trial. Am J Obstet Gynecol 1994; 171 (03) 818-822
• 8 Magee LA, Yong PJ, Espinosa V, Côté AM, Chen I, von Dadelszen P. Expectant management of severe preeclampsia remote from term: a structured systematic review. Hypertens Pregnancy 2009; 28 (03) 312-347
• 9 Sibai BM. Publications Committee, Society for Maternal-Fetal Medicine. Evaluation and management of severe preeclampsia before 34 weeks' gestation. Am J Obstet Gynecol 2011; 205 (03) 191-198
• 10 Fishel Bartal M, Lindheimer MD, Sibai BM. Proteinuria during pregnancy: definition, pathophysiology, methodology, and clinical significance. Am J Obstet Gynecol 2022; 226 (2S): S819-S834
• 11 American College of O. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013; 122 (05) 1122-1131
• 12 Dong X, Gou W, Li C. et al. Proteinuria in preeclampsia: not essential to diagnosis but related to disease severity and fetal outcomes. Pregnancy Hypertens 2017; 8: 60-64
• 13 Guida JP, Parpinelli MA, Surita FG, Costa ML. The impact of proteinuria on maternal and perinatal outcomes among women with pre-eclampsia. Int J Gynaecol Obstet 2018; 143 (01) 101-107
• 14 Kim MJ, Kim YN, Jung EJ. et al. Is massive proteinuria associated with maternal and fetal morbidities in preeclampsia?. Obstet Gynecol Sci 2017; 60 (03) 260-265
• 15 Newman MG, Robichaux AG, Stedman CM. et al. Perinatal outcomes in preeclampsia that is complicated by massive proteinuria. Am J Obstet Gynecol 2003; 188 (01) 264-268
• 16 Bouzari Z, Javadiankutenai M, Darzi A, Barat S. Does proteinura in preeclampsia have enough value to predict pregnancy outcome?. Clin Exp Obstet Gynecol 2014; 41 (02) 163-168
• 17 Mateus J, Newman R, Sibai BM. et al. Massive urinary protein excretion associated with greater neonatal risk in preeclampsia. AJP Rep 2017; 7 (01) e49-e58
• 18 Özkara A, Kaya AE, Başbuğ A. et al. Proteinuria in preeclampsia: is it important?. Ginekol Pol 2018; 89 (05) 256-261
• 19 Tanacan A, Fadiloglu E, Beksac MS. The importance of proteinuria in preeclampsia and its predictive role in maternal and neonatal outcomes. Hypertens Pregnancy 2019; 38 (02) 111-118
• 20 Rodriguez-Thompson D, Lieberman ES. Use of a random urinary protein-to-creatinine ratio for the diagnosis of significant proteinuria during pregnancy. Am J Obstet Gynecol 2001; 185 (04) 808-811
• 21 Brown RA, Kemp GJ, Walkinshaw SA, Howse M. Pregnancies complicated by preeclampsia and non-preeclampsia-related nephrotic range proteinuria. Obstet Med 2013; 6 (04) 159-164
• 22 Sanjanwala AR, Jauk VC, Cozzi GD. et al. Outcomes before and after adopting guidelines for expectant management of severe preeclampsia. Am J Perinatol 2022; 39 (02) 172-179
• 23 Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol 2008; 294 (02) H541-H550
• 24 Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction. Hypertension 2001; 38 (3 Pt 2): 718-722
• 25 Svenningsen P, Friis UG, Versland JB. et al. Mechanisms of renal NaCl retention in proteinuric disease. Acta Physiol (Oxf) 2013; 207 (03) 536-545
• 26 Stillman IE, Karumanchi SA. The glomerular injury of preeclampsia. J Am Soc Nephrol 2007; 18 (08) 2281-2284